Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2014

01-11-2014 | Review

Safety and efficacy of progressive resistance training in breast cancer: a systematic review and meta-analysis

Authors: Birinder S. Cheema, Sharon L. Kilbreath, Paul P. Fahey, Geoffrey P. Delaney, Evan Atlantis

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Login to get access

Abstract

The purpose of this study was to assess the safety and efficacy of progressive resistance training (PRT) in breast cancer. Randomized controlled trials (RCTs) published to November 2013 that reported on the effects of PRT (>6 weeks) on breast cancer-related lymphedema (BCRL) (incidence/exacerbation, arm volume, and symptom severity), physical functioning (upper and lower body muscular strength), and health-related quality of life (HRQoL) in breast cancer patients were included. Of 446 citations retrieved, 15 RCTs in 1,652 patients were included and yielded five studies on BCRL incidence/exacerbation (N = 647), four studies on arm volume (N = 384) and BCRL symptom severity (N = 479), 11 studies on upper body muscular strength (N = 1,252), nine studies on lower body muscular strength (N = 1,079), and seven studies on HRQoL (N = 823). PRT reduced the risk of BCRL versus control conditions [OR = 0.53 (95 % CI 0.31–0.90); I 2 = 0 %] and did not worsen arm volume or symptom severity (both SMD = −0.07). PRT significantly improved upper [SMD = 0.57 (95 % CI 0.37–0.76); I 2 = 58.4 %] and lower body muscular strength [SMD = 0.48 (95 % CI 0.30–0.67); I 2 = 46.7 %] but not HRQoL [SMD = 0.17 (95 % CI −0.03 to 0.38); I 2  = 47.0 %]. The effect of PRT on HRQoL became significant in our sensitivity analysis when two studies conducted during adjuvant chemotherapy [SMD = 0.30 (95 % CI 0.04–0.55), I 2 = 37.0 %] were excluded. These data indicate that PRT improves physical functioning and reduces the risk of BCRL. Clinical practice guidelines should be updated to inform clinicians on the benefits of PRT in this cohort.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef
2.
3.
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J et al (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760):127–138PubMedCentralPubMedCrossRef
4.
Bray F, Ren J-S, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132(5):1133–1145PubMedCrossRef
5.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62PubMedCrossRef
6.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
7.
Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA (2013) Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer 119(7):1402–1411PubMedCentralPubMedCrossRef
8.
Dominick SA, Madlensky L, Natarajan L, Pierce JP (2013) Risk factors associated with breast cancer-related lymphedema in the WHEL Study. J Cancer Surv 7(1):115–123CrossRef
9.
Harrington S, Padua D, Battaglini C, Michener LA (2013) Upper extremity strength and range of motion and their relationship to function in breast cancer survivors. Physiother Theory Pract 29(7):513–520PubMedCrossRef
10.
Reinertsen KV, Cvancarova M, Loge JH, Edvardsen H, Wist E, Fossa SD (2010) Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surv 4(4):405–414CrossRef
11.
Vance V, Mourtzakis M, McCargar L, Hanning R (2011) Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 12(4):282–294PubMedCrossRef
12.
Villasenor A, Ballard-Barbash R, Baumgartner K, Baumgartner R, Bernstein L, McTiernan A, Neuhouser ML (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surv 6(4):398–406CrossRef
13.
Chen Z, Maricic M, Bassford TL et al (2005) Fracture risk among breast cancer survivors: results from the women’s health initiative observational study. Arch Intern Med 165(5):552–558PubMedCrossRef
14.
Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A et al (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27(21):3437–3444PubMedCentralPubMedCrossRef
15.
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69(13):5383–5391PubMedCentralPubMedCrossRef
16.
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK (2012) Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer 20(10):2433–2439PubMedCrossRef
17.
Galiano-Castillo N, Ariza-Garcia A, Cantarero-Villanueva I, Fernandez-Lao C, Diaz-Rodriguez L, Arroyo-Morales M (2013) Depressed mood in breast cancer survivors: associations with physical activity, cancer-related fatigue, quality of life, and fitness level. Eur J Oncol Nurs 18(2):206–210PubMedCrossRef
18.
Kwan ML, Sternfeld B, Ergas IJ, Timperi AW, Roh JM, Hong CC, Quesenberry CP, Kushi LH (2012) Change in physical activity during active treatment in a prospective study of breast cancer survivors. Breast Cancer Res Treat 131(2):679–690PubMedCentralPubMedCrossRef
19.
Smoot B, Johnson M, Duda JJ, Krasnoff J, Dodd M (2012) Cardiorespiratory fitness in women with and without lymphedema following breast cancer treatment. Cancer Clin Oncol 1(1):21–31PubMedCentralPubMed
20.
Pinto M, Gimigliano F, Tatangelo F, Megna M, Izzo F, Gimigliano R, Iolascon G (2013) Upper limb function and quality of life in breast cancer related lymphedema: a cross-sectional study. Eur J Phys Rehabil Med 49(5):665–673PubMed
21.
Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5):386–405PubMedCrossRef
22.
Sehl M, Lu X, Silliman R, Ganz PA (2013) Decline in physical functioning in first 2 years after breast cancer diagnosis predicts 10-year survival in older women. J Cancer Surv 7(1):20–31CrossRef
23.
Epplein M, Zheng Y, Zheng W, Chen Z, Gu K, Penson D, Lu W, Shu XO (2011) Quality of life after breast cancer diagnosis and survival. J Clin Oncol 29(4):406–412PubMedCentralPubMedCrossRef
24.
Cheema B, Gaul C, Lane K, Fiatarone Singh MA (2008) Progressive resistance training in breast cancer: a systematic review of clinical trials. Breast Cancer Res Treat 109:9–26PubMedCrossRef
25.
Demark-Wahnefried W (2009) A weighty matter—lifting after breast cancer. N Engl J Med 361(7):710–711PubMedCrossRef
26.
Ahmed R, Thomas W, Yee D, Schmitz K (2006) Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J Clin Oncol 24(18):2765–2772PubMedCrossRef
27.
Ohira T, Schmitz K, Ahmed R, Yee D (2006) Effects of weight training on quality of life in recent breast cancer survivors. Cancer 106:2076–2083PubMedCrossRef
28.
Courneya K, Segal R, Mackey J, Gelmon K, Reid R, Friedenreich C, Ladha A, Proulx C, Vallance J, Lane K et al (2007) Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 25(28):4396–4404PubMedCrossRef
29.
Schwartz AL, Winters-Stone K, Gallucci B (2007) Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 34(3):627–633PubMedCrossRef
30.
Twiss JJ, Waltman NL, Berg K, Ott CD, Gross GJ, Lindsey AM (2009) An exercise intervention for breast cancer survivors with bone loss. J Nurs Scholarsh 41(1):20–27PubMedCrossRef
31.
Schmitz K, Ahmed R, Troxel A, Cheville A, Smith R, Lewis-Grant L, Bryan C, Williams-Smith C, Greene Q (2009) Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med 361:664–673PubMedCrossRef
32.
Schmitz KH, Ahmed RL, Troxel AB, Cheville A, Lewis-Grant L, Smith R, Bryan CJ, Williams-Smith CT, Chittams J (2010) Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA 304(24):2699–2705PubMedCrossRef
33.
Speck RM, Gross CR, Hormes JM, Ahmed RL, Lytle LA, Hwang WT, Schmitz KH (2010) Changes in the Body Image and Relationship Scale following a one-year strength training trial for breast cancer survivors with or at risk for lymphedema. Breast Cancer Res Treat 121(2):421–430PubMedCrossRef
34.
Kim do S, Sim YJ, Jeong HJ, Kim GC (2010) Effect of active resistive exercise on breast cancer-related lymphedema: a randomized controlled trial. Arch Phys Med Rehabil 91(12):1844–1848PubMedCrossRef
35.
Winters-Stone KM, Dobek J, Bennett JA, Nail LM, Leo MC, Schwartz A (2012) The effect of resistance training on muscle strength and physical function in older, postmenopausal breast cancer survivors: a randomized controlled trial. J Cancer Surv 6(2):189–199CrossRef
36.
Musanti R (2012) A study of exercise modality and physical self-esteem in breast cancer survivors. Med Sci Sports Exerc 44(2):352–361PubMedCrossRef
37.
Kilbreath SL, Refshauge KM, Beith JM, Ward LC, Lee M, Simpson JM, Hansen R (2012) Upper limb progressive resistance training and stretching exercises following surgery for early breast cancer: a randomized controlled trial. Breast Cancer Res Treat 133(2):667–676PubMedCrossRef
38.
Winters-Stone KM, Dobek J, Nail LM, Bennett JA, Leo MC, Torgrimson-Ojerio B, Luoh SW, Schwartz A (2013) Impact + resistance training improves bone health and body composition in prematurely menopausal breast cancer survivors: a randomized controlled trial. Osteoporos Int 24(5):1637–1646PubMedCrossRef
39.
Cormie P, Pumpa K, Galvao DA, Turner E, Spry N, Saunders C, Zissiadis Y, Newton RU (2013) Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomised controlled trial. J Cancer Surv 7(3):413–424CrossRef
40.
Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Cook D, Jespersen D, Proulx C et al (2013) Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst 105(23):1821–1832PubMedCrossRef
41.
Aebi S, Davidson T, Gruber G, Cardoso F (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi12–vi24
42.
Yarnold J (2009) Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence guideline 2009. Clin Oncol 21(3):159–160CrossRef
43.
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ (2009) Breast cancer. J Natl Compr Canc Netw 7(2):122–192PubMed
44.
45.
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P et al (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14(10):2756–2768PubMed
46.
47.
48.
Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions, version 5.1.0
49.
Haldane JB (1956) The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 20(4):309–311PubMedCrossRef
50.
Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23(9):1351–1375PubMedCrossRef
51.
Higgins J, Thompson S, Deeks J, Altman D (2003) Measuring inconsistency in meta-analysis. Br Med J 327(7414):557–560CrossRef
52.
Higgins J, Thompson S (2002) Quantifying heterogeneity in meta-analysis. Stat Med 21(11):1539–1558PubMedCrossRef
53.
Eggers M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315(7109):629–634CrossRef
54.
Norman SA, Miller LT, Erikson HB, Norman MF, McCorkle R (2001) Development and validation of a telephone questionnaire to characterize lymphedema in women treated for breast cancer. Phys Ther 81(6):1192–1205PubMed
55.
Schmitz K, Ahmed R, Hannan P, Yee D (2005) Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin and insulin-like growth factor axis proteins. Cancer Epidemiol Biomark Prev 14(7):1672–1680CrossRef
56.
Brown JC, Troxel AB, Schmitz KH (2012) Safety of weightlifting among women with or at risk for breast cancer-related lymphedema: musculoskeletal injuries and health care use in a weightlifting rehabilitation trial. Oncologist 17(8):1120–1128PubMedCentralPubMedCrossRef
57.
Hayes SC, Janda M, Cornish B, Battistutta D, Newman B (2008) Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol 26(21):3536–3542PubMedCrossRef
58.
Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH (2012) Upper-body morbidity after breast cancer. Cancer 118(S8):2237–2249PubMedCrossRef
59.
Beaulac S, McNair L, Scott T, LaMorte W, Kavanah M (2002) Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg 137(11):1253–1257PubMedCrossRef
60.
Ahmed RL, Schmitz KH, Prizment AE, Folsom AR (2011) Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res Treat 130(3):981–991PubMedCentralPubMedCrossRef
61.
Sagen A, Kaaresen R, Sandvik L, Thune I, Risberg MA (2014) Upper limb physical function and adverse effects after breast cancer surgery: a prospective 2.5-year follow-up study and preoperative measures. Arch Phys Med Rehabil 95(5):875–881PubMedCrossRef
62.
Simonavice E, Liu P-Y, Ilich JZ, Kim J-S, Panton LB (2011) Body composition, muscular strength, and physical function in breast cancer survivors. Int J Body Compos Res 9(2):57–64
63.
Goodpaster B, Park S, Harris T, Kritchevsky S, Nevitt M, Schwartz A, Simonsick E, Tylavsky F, Visser M, Newman A (2006) The loss of skeletal muscle strength, mass, and quality in older adults: the Health, Aging and Body Composition Study. J Gerontol 61A(10):1059–1064CrossRef
64.
Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB (2006) Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol Ser A 61(1):72–77CrossRef
65.
Takata Y, Shimada M, Ansai T, Yoshitake Y, Nishimuta M, Nakagawa N, Ohashi M, Yoshihara A, Miyazaki H (2012) Physical performance and 10-year mortality in a 70-year-old community-dwelling population. Aging Clin Exp Res 24(3):257–264PubMed
66.
Lee ES, Lee MK, Kim SH, Ro JS, Kang HS, Kim SW, Lee KS, Yun YH (2011) Health-related quality of life in survivors with breast cancer 1 year after diagnosis compared with the general population: a prospective cohort study. Ann Surg 253(1):101–108PubMedCrossRef
67.
Klein D, Mercier M, Abeilard E, Puyraveau M, Danzon A, Dalstein V, Pozet A, Guizard A-V, Henry-Amar M, Velten M (2011) Long-term quality of life after breast cancer: a French registry-based controlled study. Breast Cancer Res Treat 129(1):125–134PubMedCrossRef
68.
Alfano CM, Smith AW, Irwin ML, Bowen DJ, Sorensen B, Reeve BB, Meeske KA, Bernstein L, Baumgartner KB, Ballard-Barbash R et al (2007) Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis. J Cancer Surv 1(2):116–128CrossRef
69.
Blanchard CM, Courneya KS, Stein K (2008) Cancer survivors’ adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society’s SCS-II. J Clin Oncol 26(13):2198–2204PubMedCrossRef
70.
Merchant CR, Chapman T, Kilbreath SL, Refshauge KM, Krupa K (2008) Decreased muscle strength following management of breast cancer. Disabil Rehabil 30(15):1098–1105PubMedCrossRef
Metadata
Title
Safety and efficacy of progressive resistance training in breast cancer: a systematic review and meta-analysis
Authors
Birinder S. Cheema
Sharon L. Kilbreath
Paul P. Fahey
Geoffrey P. Delaney
Evan Atlantis
Publication date
01-11-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3162-9

Other articles of this Issue 2/2014

Breast Cancer Research and Treatment 2/2014 Go to the issue

Epidemiology

Racial and ethnic disparities in the diagnosis of breast cancer: changes in presenting stage in minority populations in Florida during 1981–2009

Clinical trial

Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial

Epidemiology

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research

Preclinical Study

Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs

Clinical trial

Frozen section evaluation of breast carcinoma sentinel lymph nodes: a retrospective review of 1,940 cases

Epidemiology

High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits